CXCL12 and type 2 diabetes mellitus: Another approach to understand the mechanism behind gliptin-associated BP was to investigate how the use of gliptins in patients with BP and T2D modifies the amount of the chemokine SDF-1, one of the best characterized substrates of DPP4.